Serum progesterone (P) levels are critical for endometrial receptivity and implantation in frozen-thawed embryo transfer (FET) cycles. However, the prognostic role of P levels measured on the day of the β-human chorionic gonadotropin (β-hCG) pregnancy test has not been fully elucidated. This study aimed to evaluate the association between β-hCG day serum P levels and pregnancy outcomes in FET cycles. This retrospective cohort study included 621 FET cycles performed between January 2023 and December 2024, of which 79.5% were conducted using hormone replacement therapy (HRT) protocols and 20.5% using natural cycle (NC) protocols. Serum P levels were measured on the day of the β-hCG pregnancy test. Receiver operating characteristic (ROC) curve analysis was used to determine protocol-specific P thresholds for predicting ongoing pregnancy (OPR). Ongoing pregnancy was defined as a viable intrauterine pregnancy confirmed by ultrasound at or beyond 12 weeks of gestation. Multivariable logistic regression was applied to identify independent predictors of OPR. ROC analysis identified optimal P thresholds of 15.5 ng/mL in NC cycles (AUC 0.821) and 14.15 ng/mL in HRT cycles (AUC 0.595). Overall, 44% of patients had serum P levels below the protocol-specific threshold. OPR was significantly higher in patients with P levels above the threshold (NC: 63.0% vs. 12.8%; HRT: 48.1% vs. 31.9%; p < 0.001). Multivariable regression demonstrated that younger maternal age and higher β-hCG day P levels independently predicted OPR. In HRT cycles, blastocyst-stage transfer was also significantly associated with improved outcomes (OR = 0.27, 95% CI 0.13-0.59; p < 0.05). Serum P levels measured on the day of the β-hCG test are significantly associated with pregnancy outcomes in both HRT and NC FET cycles. Routine monitoring of late luteal P levels and individualized luteal phase support strategies may enhance clinical success rates.
progesterone FET outcomes, beta-hCG day progesterone, frozen embryo transfer pregnancy prediction, serum progesterone endometrial receptivity, progesterone threshold FET, ROC curve progesterone cutoff, implantation progesterone level, retrospective cohort FET, luteal phase progesterone monitoring, pregnancy outcome prediction FET
PMID 41554756 41554756 DOI 10.1038/s41598-025-30902-9 10.1038/s41598-025-30902-9
Cite this article
Girouard, L. G., & Holm, R. C. (2001). The role of natural progesterone in natural hormone replacement therapy. *International Journal of Pharmaceutical Compounding*, *5*(3), 218-220.
Girouard LG, Holm RC. The role of natural progesterone in natural hormone replacement therapy. Int J Pharm Compd. 2001;5(3):218-220.
Girouard, L. G., and R. C. Holm. "The role of natural progesterone in natural hormone replacement therapy." *International Journal of Pharmaceutical Compounding*, vol. 5, no. 3, 2001, pp. 218-220.
STUDY QUESTION: Is there a difference in live birth rates at 24 months between infertile women with polycystic ovary syndrome (PCOS) who have normal versus abnormal glucose metabolism?
SUMMARY ANSWER...
PURPOSE: To evaluate the clinical relevance of serum progesterone levels on the day of frozen embryo transfer (FET) and the dose of vaginal progesterone gel (Crinone) used for early luteal phase suppo...
Brand KM et al., 2025Women's health (London, England)
Influential guidelines have supported the role of metformin in the management of polycystic ovary syndrome (PCOS) for a number of years. However, regulatory approvals for this therapeutic indication a...
PURPOSE: To evaluate the effectiveness and safety of the novel protocol-progestin-primed ovarian stimulation (PPOS) protocol during controlled ovarian hyperstimulation (COH), in patients undergoing in...